Search Results - "McGregor, Lisa"

A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors by Santana, Victor M., Sahr, Natasha, Tatevossian, Ruth G., Jia, Sujuan, Campagne, Olivia, Sykes, April, Stewart, Clinton F., Furman, Wayne L., McGregor, Lisa M.

“…Background The prognosis for children with recurrent solid tumors generally is poor. Targeting mammalian target of rapamycin (mTOR) and vascular endothelial…”
Get full text

Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma by NAVID, Fariba, SONDEL, Paul M, GOLDBERG, Jacob, HANK, Jacquelyn A, BILLUPS, Catherine A, JIANRONG WU, FURMAN, Wayne L, MCGREGOR, Lisa M, OTTO, Mario, GILLIES, Stephen D, HANDGRETINGER, Rupert, SANTANA, Victor M, BARFIELD, Raymond, SHULKIN, Barry L, KAUFMAN, Robert A, ALLAY, Jim A, GAN, Jacek, HUTSON, Paul, SONGWON SEO, KYUNGMANN KIM

“…The addition of immunotherapy, including a combination of anti-GD2 monoclonal antibody (mAb), ch14.18, and cytokines, improves outcome for patients with…”
Get full text

Chronic pain in children and adolescents diagnosed with cancer: the challenge of mitigating the pain and the potential of integrating exercise into pain management by Caru, Maxime, Alberts, Nicole M., Freeman, Michelle C., Dandekar, Smita C., Rao, Pooja, McKeone, Daniel J., Brown, Valerie I., McGregor, Lisa M., Schmitz, Kathryn H.

“…  Background Pain is one of the most common and distressing symptoms experienced by children and adolescents diagnosed with cancer. It is vital that children…”
Get full text

Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors by NAVID, Fariba, BAKER, Sharyn D, SHUIYING HU, PANETTA, John C, TURNER, David, FOFANA, Demba, REDDICK, Wilburn E, LEUNG, Wing, SANTANA, Victor M, BETH MCCARVILLE, M, STEWART, Clinton F, BILLUPS, Catherine A, JIANRONG WU, DAVIDOFF, Andrew M, SPUNT, Sheri L, FURMAN, Wayne L, MCGREGOR, Lisa M

“…To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, and pharmacodynamics of sorafenib, bevacizumab, and low-dose…”
Get full text

Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma by Pai Panandiker, Atmaram S., Beltran, Chris, Billups, Catherine A., McGregor, Lisa M., Furman, Wayne L., Davidoff, Andrew M.

“…Background Locoregional failure is a significant concern in patients with high‐risk abdominal neuroblastoma (NB) receiving radiotherapy. Locoregional control…”
Get full text

A novel EWSR1-CREB3L1 fusion transcript in a case of small cell osteosarcoma by Debelenko, Larisa V., McGregor, Lisa M., Shivakumar, Bangalore R., Dorfman, Howard D., Raimondi, Susana C.

“…Cellular morphology of small cell osteosarcoma, an aggressive variant of osteosarcoma, is similar to Ewing sarcoma, but its molecular pathogenesis is largely…”
Get full text

The promotion of HL-1 cardiomyocyte beating using anisotropic collagen-GAG scaffolds by Gonnerman, Emily A, Kelkhoff, Douglas O, McGregor, Lisa M, Harley, Brendan A.C

“…Abstract Biomaterials for myocardial tissue engineering must balance structural, mechanical and bioactivity concerns. This work describes the interaction…”
Get full text

Margin status and tumor recurrence after nephron-sparing surgery for bilateral Wilms tumor by Kieran, Kathleen, Williams, Mark A, Dome, Jeffrey S, McGregor, Lisa M, Krasin, Matthew J, Davidoff, Andrew M

“…Abstract Purpose Nephron-sparing surgery (NSS) has been advocated for patients with bilateral Wilms tumor (BWT). We sought to determine whether margin status…”
Get full text

Repeat nephron-sparing surgery for children with bilateral Wilms tumor by Kieran, Kathleen, Williams, Mark A, McGregor, Lisa M, Dome, Jeffrey S, Krasin, Matthew J, Davidoff, Andrew M

“…Abstract Background Renal insufficiency is a significant complication of Wilms tumor treatment in the 5% with bilateral disease. Nephron-sparing surgery (NSS)…”
Get full text

Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identifies Topotecan as a Potential Chemotherapeutic Agent by PINTO, Emilia M, MORTON, Christopher, RODRIGUEZ-GALINDO, Carlos, MCGREGOR, Lisa, DAVIDOFF, Andrew M, MERCER, Kimberly, DEBELENKO, Larisa V, BILLUPS, Catherine, RIBEIRO, Raul C, ZAMBETTI, Gerard P

“…Pediatric adrenocortical carcinoma (ACC) is a rare and highly aggressive malignancy. Conventional chemotherapeutic agents have shown limited utility and are…”
Get full text

UGT1A1 Promoter Genotype Correlates With SN-38 Pharmacokinetics, but Not Severe Toxicity in Patients Receiving Low-Dose Irinotecan by STEWART, Clinton F, PANETTA, John C, FURMAN, Wayne L, MCGREGOR, Lisa M, O'SHAUGHNESSY, Melinda A, THROM, Stacy L, FRAGA, Charles H, OWENS, Thandranese, TIEBIN LIU, BILLUPS, Catherine, RODRIGUEZ-GALINDO, Carlos, GAJJAR, Amar

“…To study the association between UDP-glucuronosyltransferase 1A1 (UGT1A1) genotypes and severe toxicity as well as irinotecan disposition in pediatric patients…”
Get full text

Attendance at National Cancer Institute and Children's Oncology Group Facilities for Children, Adolescents, and Young Adults with Cancer in Pennsylvania: A Population-Based Study by Rao, Pooja, Segel, Joel E, McGregor, Lisa M, Lengerich, Eugene J, Drabick, Joseph J, Miller, Barbara

“…Adolescents and young adults (AYAs) with cancer are a vulnerable population with decreased attendance at National Cancer Institute (NCI) comprehensive cancer…”
Get more information

Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors by FURMAN, Wayne L, NAVID, Fariba, GAJJAR, Amar J, HOUGHTON, Peter J, SANTANA, Victor M, STEWART, Clinton F, DAW, Najat C, MCCARVILLE, M. Beth, MCGREGOR, Lisa M, SPUNT, Sheri L, RODRIGUEZ-GALINDO, Carlos, PANETTA, John C, CREWS, Kristine R, JIANRONG WU

“…To assess the maximum-tolerated dosages (MTDs), and dose-limiting toxicities (DLTs) of the epidermal growth factor receptor inhibitor gefitinib and of…”
Get full text

Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma by Federico, Sara M, Allewelt, Heather B, Spunt, Sheri L, Hudson, Melissa M, Wu, Jianrong, Billups, Catherine A, Jenkins, Jesse, Santana, Victor M, Furman, Wayne L, McGregor, Lisa M

“…Most prior studies evaluating subsequent malignant neoplasms (SMNs) in patients with neuroblastoma are restricted to long-term survivors and/or their treatment…”
Get full text

Disease control intervals in high‐risk neuroblastoma by Santana, Victor M., Furman, Wayne L., McGregor, Lisa M., Billups, Catherine A.

“…BACKGROUND. Current salvage therapy for recurrent high‐risk neuroblastoma is rarely curative. Assessment of the effectiveness of new, primarily cytostatic…”
Get full text

Pediatric cancers in the new millennium: dramatic progress, new challenges by McGregor, Lisa M, Metzger, Monika L, Sanders, Robert, Santana, Victor M

“…Over the past 50 years, great strides have been made in diagnosis, treatment, and survival of childhood cancer. In the 1960s the probability of survival for a…”
Get more information

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma by Furman, Wayne L., McGregor, Lisa M., McCarville, M. Beth, Onciu, Mihaela, Davidoff, Andrew M., Kovach, Sandy, Hawkins, Dana, McPherson, Valerie, Houghton, Peter J., Billups, Catherine A., Wu, Jianrong, Stewart, Clinton F., Santana, Victor M.

“…Summary Background Gefitinib potently inhibits neuroblastoma proliferation in vitro , and the gefitinib/irinotecan combination shows greater than additive…”
Get full text

Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors by McGregor, Lisa M., Stewart, Clinton F., Crews, Kristine R., Tagen, Michael, Wozniak, Amy, Wu, Jianrong, McCarville, M. Beth, Navid, Fariba, Santana, Victor M., Houghton, Peter J., Furman, Wayne L., Rodriguez-Galindo, Carlos

“…Background Administration of an oral cephalosporin allowed advancement of the dosage of oral irinotecan. This study investigates whether administration of an…”
Get full text

Jaw Dysfunction Related to Pterygoid and Masseter Muscle Dosimetry After Radiation Therapy in Children and Young Adults With Head-and-Neck Sarcomas by Krasin, Matthew J., M.D, Wiese, Kristin M., P.T., D.P.T, Spunt, Sheri L., M.D, Hua, Chia-ho, Ph.D, Daw, Najat, M.D, Navid, Fariba, M.D, Davidoff, Andrew M., M.D, McGregor, Lisa, M.D., Ph.D, Merchant, Thomas E., D.O., Ph.D, Kun, Larry E., M.D, McCrarey, Lola, P.T, Hoth, Kelly A., B.S, Yan, Xiaowei, M.S, Xiong, Xiaoping, Ph.D

“…Purpose To investigate the relationship between jaw function, patient and treatment variables, and radiation dosimetry of the mandibular muscles and joints in…”
Get full text

Locoregional Tumor Progression After Radiation Therapy Influences Overall Survival in Pediatric Patients With Neuroblastoma by Pai Panandiker, Atmaram S., M.D, McGregor, Lisa, M.D., Ph.D, Krasin, Matthew J., M.D, Wu, Shengjie, M.S, Xiong, Xiaoping, Ph.D, Merchant, Thomas E., D.O., Ph.D

“…Purpose There is renewed attention to primary site irradiation and local control for patients with high-risk neuroblastoma (NB). We conducted a retrospective…”
Get full text